Detalles de la búsqueda
1.
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Lancet
; 402(10397): 185-195, 2023 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37290461
2.
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(7): 888-898, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35688173
3.
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
BMC Cancer
; 21(1): 904, 2021 Aug 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34364385
4.
Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.
Oncologist
; 24(11): 1497-1501, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31399500
5.
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma.
Br J Cancer
; 118(9): 1176-1178, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29576624
6.
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
N Engl J Med
; 373(19): 1814-23, 2015 Nov 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26406150
7.
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 17(7): 917-927, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27279544
8.
Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
BMC Cancer
; 21(1): 1023, 2021 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34525968
9.
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
J Clin Oncol
; 41(9): 1747-1757, 2023 03 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36512738
10.
Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial.
Eur J Cancer
; 177: 63-71, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36327527
11.
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study.
J Clin Oncol
; 39(33): 3725-3736, 2021 11 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-34491815
12.
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
Eur J Cancer
; 94: 115-125, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29550566
13.
Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
J Clin Oncol
; 36(8): 757-764, 2018 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29377755
14.
Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.
Transplantation
; 83(3): 314-22, 2007 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17297406
15.
Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.
Eur J Cancer
; 86: 296-304, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29059635
16.
Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Cancer Res
; 62(20): 5785-91, 2002 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12384539
17.
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.
Eur Urol
; 67(2): 310-8, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24631409
18.
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.
Clin Cancer Res
; 20(1): 233-45, 2014 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24166903
19.
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
J Clin Oncol
; 32(30): 3391-9, 2014 Oct 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-25225437
20.
Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125].
Eur J Cancer
; 103: 287, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30270112